IL117116A0 - A medical composition for the in vivo transfection and expression of exogenes - Google Patents

A medical composition for the in vivo transfection and expression of exogenes

Info

Publication number
IL117116A0
IL117116A0 IL11711696A IL11711696A IL117116A0 IL 117116 A0 IL117116 A0 IL 117116A0 IL 11711696 A IL11711696 A IL 11711696A IL 11711696 A IL11711696 A IL 11711696A IL 117116 A0 IL117116 A0 IL 117116A0
Authority
IL
Israel
Prior art keywords
exogenes
expression
medical composition
vivo transfection
vivo
Prior art date
Application number
IL11711696A
Other languages
English (en)
Original Assignee
Inst Nat Sante Rech Med
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Rhone Poulenc Rorer Sa filed Critical Inst Nat Sante Rech Med
Publication of IL117116A0 publication Critical patent/IL117116A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL11711696A 1995-02-14 1996-02-12 A medical composition for the in vivo transfection and expression of exogenes IL117116A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9501662A FR2730411B1 (fr) 1995-02-14 1995-02-14 Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes

Publications (1)

Publication Number Publication Date
IL117116A0 true IL117116A0 (en) 1996-06-18

Family

ID=9476106

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11711696A IL117116A0 (en) 1995-02-14 1996-02-12 A medical composition for the in vivo transfection and expression of exogenes

Country Status (23)

Country Link
US (2) US20030004091A1 (da)
EP (1) EP0809516B1 (da)
JP (1) JPH11500430A (da)
KR (1) KR100402540B1 (da)
AT (1) ATE204481T1 (da)
AU (1) AU717218B2 (da)
BR (1) BR9607310A (da)
CA (1) CA2211039C (da)
CZ (1) CZ258197A3 (da)
DE (1) DE69614668T2 (da)
DK (1) DK0809516T3 (da)
ES (1) ES2163612T3 (da)
FI (1) FI119176B (da)
FR (1) FR2730411B1 (da)
GR (1) GR3036438T3 (da)
HU (1) HU222991B1 (da)
IL (1) IL117116A0 (da)
MX (1) MX9706017A (da)
NO (1) NO320072B1 (da)
PT (1) PT809516E (da)
SK (1) SK282235B6 (da)
WO (1) WO1996025177A1 (da)
ZA (1) ZA961161B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451571B1 (en) 1994-05-02 2002-09-17 University Of Washington Thymidine kinase mutants
EP0942747A1 (en) * 1996-08-26 1999-09-22 Chiron Corporation Postinfection human immunodeficiency virus (hiv) vaccination therapy
AU1288099A (en) 1997-10-30 1999-05-24 Cornell Research Foundation Inc. A method of inhibiting an immune response to a recombinant vector
EP1980617A1 (en) 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Improved expression of HIV polypeptides and production of virus-like particles
WO2000039304A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AU5470900A (en) * 1999-06-08 2000-12-28 Children's Hospital Of Philadelphia, The Methods for preventing formation of inhibitory antibodies in the setting of genetherapy
FR2799472B1 (fr) * 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
MXPA02010993A (es) * 2000-05-12 2003-03-10 Genzyme Corp Reguladores de transmision de la tnf-alfa.
CA2452015C (en) 2001-07-05 2012-07-03 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US7569217B2 (en) * 2001-09-24 2009-08-04 University Of Saskatchewan Porcine adenovirus E1 and E4 regions
US20030211075A1 (en) * 2001-09-27 2003-11-13 Thorpe Philip E. Combined compositions for tumor vasculature coagulation and treatment
AU2003291134A1 (en) * 2002-11-21 2004-06-18 Genzyme Corporation Use of diamide derivatives for inhibiting chronic tissue transplant rejection
PT1562571E (pt) * 2002-11-21 2011-11-25 Genzyme Corp Combinação de derivados de diamina e agentes imunossupressores para a indução da tolerância imunológica
JP2007520566A (ja) * 2004-02-04 2007-07-26 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク 自己免疫治療のための抗ｃｄ３及び抗原特異的免疫療法
WO2008013918A2 (en) * 2006-07-26 2008-01-31 Myelin Repair Foundation, Inc. Cell cycle regulation and differentiation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5962694A (en) * 1992-12-31 1994-08-15 Exemplar Corporation Producing cells for transplantation to reduce host rejection and resulting cells
AU5965294A (en) * 1993-01-08 1994-08-15 Exemplar Corporation An (in vitro)/(in vivo) method for identifying anti-neoplastic drugs
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus

Also Published As

Publication number Publication date
CA2211039A1 (fr) 1996-08-22
ATE204481T1 (de) 2001-09-15
FI973323A0 (fi) 1997-08-13
US20040265276A1 (en) 2004-12-30
CZ258197A3 (en) 1997-11-12
SK110897A3 (en) 1998-01-14
ZA961161B (en) 1996-08-07
KR19980702199A (ko) 1998-07-15
BR9607310A (pt) 1997-11-25
ES2163612T3 (es) 2002-02-01
MX9706017A (es) 1997-11-29
NO973724L (no) 1997-08-13
FR2730411B1 (fr) 1997-03-28
EP0809516B1 (fr) 2001-08-22
FI119176B (fi) 2008-08-29
DE69614668T2 (de) 2002-06-27
KR100402540B1 (ko) 2004-05-07
US20030004091A1 (en) 2003-01-02
WO1996025177A1 (fr) 1996-08-22
NO320072B1 (no) 2005-10-17
SK282235B6 (sk) 2001-12-03
FI973323L (fi) 1997-08-13
DK0809516T3 (da) 2001-12-17
CA2211039C (fr) 2011-12-06
HUP9800635A2 (hu) 1998-07-28
AU717218B2 (en) 2000-03-23
FR2730411A1 (fr) 1996-08-14
HU222991B1 (hu) 2004-01-28
HUP9800635A3 (en) 2000-12-28
NO973724D0 (no) 1997-08-13
AU4723896A (en) 1996-09-04
JPH11500430A (ja) 1999-01-12
PT809516E (pt) 2002-02-28
DE69614668D1 (de) 2001-09-27
EP0809516A1 (fr) 1997-12-03
GR3036438T3 (en) 2001-11-30

Similar Documents

Publication Publication Date Title
MX9706017A (es) Asociacion medicamentosa util para la transfeccion y la expresion in vivo de exogenes.
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
GR3032744T3 (en) Surface expression of enzyme in gene directed prodrug therapy
IL111734A0 (en) Compositions for the preparation of in vivo therapeutic products
CY2396B1 (en) Pharmaceutical composition of fenofibrate with high biological availability and method for preparingsame.
IL129445A0 (en) Improvements in or relating to diagnostic/therapeutic agents
DE69835201D1 (en) Neoglycoproteine
AU9676198A (en) Drug delivery and gene therapy delivery system
ZA961484B (en) Dna molecules preparation and use in gene therapy
AU5788096A (en) Plasmid for delivery of nucleic acids to cells and methods of use
HUP0004421A3 (en) Urea derivatives and pharmaceutical compositions containing them, use thereof for the treatment of deseases mediated by impdh enzyme
GB9709486D0 (en) Blending medical composition with sustained medicament releasability and process for preparing the same
EP0766974A3 (en) Blood reservoir, blood delivery instrument, and blood delivery apparatus
MX9801264A (es) Control de la expresion del gen de cd44 para uso terapeutico.
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
AU4378996A (en) Cell compositions for use in transplantation and ex vivo gene therapy
HUP9900317A3 (en) Pharmaceutical composition useful for nucleic acid transfection, and use thereof
AU6346898A (en) Gene therapy using bone marrow transplants transfected with therapeutic genes under the control of tissue-specific promoters
AU2001258638A1 (en) Methods for identifying modulators of the interaction between lap (latency associated peptide) and intergrin alpha.v.beta.3 and medical use thereof
HUP9904201A3 (en) Transfecting composition usable in gene therapy combining a recombinant virus incorporating an exogenous nucleic acid, a non-viral and non-plasmid transfecting agent
AU2114899A (en) Nucleotide expression systems with reduced immunogenicity for use in gene therapy
MX9706569A (es) Virus recombinantes que expresan la lecitina-colesterol aciltransferasa y sus usos en terapia genica.
ES2141044A1 (es) Terapia con oxibutinina.
MX9800697A (es) Uso de glicosidos de calendula para el tratamiento de psoriasis.
AU2298195A (en) An (in vivo) gene expression system